Tokyo, Aug. 2 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058482) titled 'A nationwide multi-institutional retrospective study to examine predictors of early postoperative recurrence in anatomically resectable pancreatic cancer treated with neoadjuvant chemotherapy (NAC-GS) (NAC-PIONEER trial)' on Aug. 1.
Study Type:
Observational
Primary Sponsor:
Institute - University of Toyama
Condition:
Condition - Resectable pancreatic cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To identify predictors of early recurrence within 6 months after surgery in patients with resectable pancreatic cancer who underwent NAC-GS.
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Invasive pancreatic ductal adenocarcinoma
Resectable pancreatic cancer
Cases of initial treatment with NAC-GS
Cases with measurable lesions
Key exclusion criteria - Cases in which NAC was introduced with a regimen other than GS
Patients who could not undergo contrast-enhanced CT imaging due to allergy
Patients who refused to participate in this study by opting out
Target Size - 5500
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 07 Month 11 Day
Date of IRB - 2025 Year 07 Month 09 Day
Anticipated trial start date - 2025 Year 08 Month 01 Day
Last follow-up date - 2027 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066138
Disclaimer: Curated by HT Syndication.
